Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Retained Earnings (2016 - 2025)

Syndax Pharmaceuticals has reported Retained Earnings over the past 11 years, most recently at -$1.5 billion for Q4 2025.

  • Quarterly results put Retained Earnings at -$1.5 billion for Q4 2025, down 23.37% from a year ago — trailing twelve months through Dec 2025 was -$1.5 billion (down 23.37% YoY), and the annual figure for FY2025 was -$1.5 billion, down 23.37%.
  • Retained Earnings for Q4 2025 was -$1.5 billion at Syndax Pharmaceuticals, down from -$1.4 billion in the prior quarter.
  • Over the last five years, Retained Earnings for SNDX hit a ceiling of -$543.7 million in Q4 2021 and a floor of -$1.5 billion in Q4 2025.
  • Median Retained Earnings over the past 5 years was -$804.4 million (2023), compared with a mean of -$909.3 million.
  • Biggest five-year swings in Retained Earnings: grew 4.38% in 2021 and later crashed 35.79% in 2024.
  • Syndax Pharmaceuticals' Retained Earnings stood at -$543.7 million in 2021, then dropped by 27.47% to -$693.0 million in 2022, then tumbled by 30.21% to -$902.4 million in 2023, then plummeted by 35.32% to -$1.2 billion in 2024, then dropped by 23.37% to -$1.5 billion in 2025.
  • The last three reported values for Retained Earnings were -$1.5 billion (Q4 2025), -$1.4 billion (Q3 2025), and -$1.4 billion (Q2 2025) per Business Quant data.